Kite Pharma, Inc.
The study was conducted for young ALL and determined a price of £530K ($649K) was justified
Canaccord believes the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit
After the impressive run up in Kite Pharma Inc shares, Stifel downgraded the stock to Hold
RBC Capital Markets reiterates its Outperform, Speculative Risk, and built an interactive KITE-APP which suggests even conservative patients/site supports strong launch potential